CAMBIA POWDER FOR SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

DICLOFENAC POTASSIUM

Tilgjengelig fra:

ARALEZ PHARMACEUTICALS CANADA INC

ATC-kode:

M01AB05

INN (International Name):

DICLOFENAC

Dosering :

50MG

Legemiddelform:

POWDER FOR SOLUTION

Sammensetning:

DICLOFENAC POTASSIUM 50MG

Administreringsrute:

ORAL

Enheter i pakken:

3/9

Resept typen:

Prescription

Terapeutisk område:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Produkt oppsummering:

Active ingredient group (AIG) number: 0122516001; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2012-03-14

Preparatomtale

_ _
_CAMBIA_
_®_
_ (diclofenac potassium) Product Monograph _
_Page 1 of 33_
PRODUCT MONOGRAPH
PR
CAMBIA
®
Diclofenac potassium powder for oral solution
50 mg
Nonsteroidal Anti-Inflammatory Drug (NSAID)
Aralez Pharmaceuticals Canada Inc.*
6733 Mississauga Road, Suite 800
Mississauga, Ontario
L5N 6J5
www.miravohealthcare.com
Date of Revision:
December 6, 2021
Submission Control No: 253454
*Doing business as (d/b/a) Miravo Healthcare
_ _
_CAMBIA_
_® _
_(diclofenac potassium) Product Monograph _
_Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................15
DRUG INTERACTIONS
..................................................................................................18
DOSAGE AND ADMINISTRATION
..............................................................................22
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL PHARMACOLOGY
............................................................23
STORAGE AND STABILITY
..........................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
................................................................................26
PHARMACEUTICAL INFORMATION
...............................................................